Log in

Avadel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AVDL)

$3.59
+0.04 (+1.13 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$3.41
Now: $3.59
$3.69
50-Day Range
$2.13
MA: $3.23
$4.42
52-Week Range
$1.03
Now: $3.59
$5.37
Volume177,073 shs
Average Volume905,367 shs
Market Capitalization$134.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVDL
CUSIPN/A
Phone353-1485-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.27 million
Book Value$0.08 per share

Profitability

Net Income$-95,300,000.00
Net Margins-135.48%

Miscellaneous

Employees144
Market Cap$134.45 million
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.


Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How will Avadel Pharmaceuticals' stock buyback program work?

Avadel Pharmaceuticals declared that its Board of Directors has authorized a share buyback program on Wednesday, March 28th 2018, which allows the company to buyback $7,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 2.7% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its quarterly earnings results on Friday, August, 9th. The company reported ($0.23) EPS for the quarter. The firm earned $17.55 million during the quarter. Avadel Pharmaceuticals had a negative return on equity of 608.04% and a negative net margin of 135.48%. View Avadel Pharmaceuticals' Earnings History.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Avadel Pharmaceuticals.

What price target have analysts set for AVDL?

2 brokerages have issued twelve-month price targets for Avadel Pharmaceuticals' shares. Their predictions range from $6.00 to $6.00. On average, they expect Avadel Pharmaceuticals' share price to reach $6.00 in the next year. This suggests a possible upside of 67.1% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.

What is the consensus analysts' recommendation for Avadel Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.

Has Avadel Pharmaceuticals been receiving favorable news coverage?

News headlines about AVDL stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a news impact score of -1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Avadel Pharmaceuticals.

Who are some of Avadel Pharmaceuticals' key competitors?

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Chaarat Gold (CGH), Fossil Group (FOSL), Associated British Foods (ABF), AMC Entertainment (AMC), First Data (FDC), Ciena (CIEN), Apollo Global Management (APO) and Cypress Semiconductor (CY).

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
  • Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
  • Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)
  • Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52)

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Investors Asset Management of Georgia Inc. GA ADV (0.10%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, James E Flynn, Michael S Anderson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

Which major investors are buying Avadel Pharmaceuticals stock?

AVDL stock was bought by a variety of institutional investors in the last quarter, including Investors Asset Management of Georgia Inc. GA ADV. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton and Michael S Anderson. View Insider Buying and Selling for Avadel Pharmaceuticals.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $3.59.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $134.45 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is http://www.avadel.com/.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]


MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  248 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel